IR@PKUHSC  > 北京大学公共卫生学院
学科主题公共卫生
Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population
Tian, Jun1; Qin, Xueying1; Fang, Kai1; Chen, Qing2; Hou, Jing3,4; Li, Juan5; Yu, Wenzhen3,4; Chen, Dafang1; Hu, Yonghua1; Li, Xiaoxin3,4
关键词Arms2 Bevacizumab Cfh Htra1 Neovascular Age-related Macular Degeneration Pharmacogenetics
刊名PHARMACOGENOMICS
2012-05-01
DOI10.2217/PGS.12.53
13期:7页:779-787
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]COMPLEMENT FACTOR-H ; ENDOTHELIAL GROWTH-FACTOR ; HTRA1 PROMOTER POLYMORPHISM ; INTRAVITREAL BEVACIZUMAB ; RISK ; RANIBIZUMAB ; VARIANT ; MULTICENTER ; SERPING1 ; SMOKING
英文摘要

Aims: To determine whether there is an association between CFH, ARMS2, HTRA1, VEGF, SERPING1 or C3 genotypes and patient response to treatment with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD). Materials & methods: This was a multicenter prospective study. One hundred and forty four patients with neovascular AMD treated with bevacizumab were recruited from 13 centers. Twelve SNPs were genotyped using Sequenom. Visual acuity score (VAS), central retinal thickness and maximum thickness of lesion were measured at each visit. Results: For the CFH rs800292 polymorphism, mean VAS changes were 4.4, 8.7 and 15.5 letters in the CC, CT and TT genotype carriers (p = 0.009). For ARMS2 rs10490924, mean VAS changes were 3.6, 12.1 and 9.6 letters for the TT, TG and GG genotypes (p = 0.001). For HTRA1 rs11200638, mean VAS changes were 3.6, 12.3 and 9.6 letters for the AA, AG and GG genotypes (p < 0.001). Conclusion: CFH, ARMS2 and HTRA1 genotypes may influence patient response to treatment with intravitreal bevacizumab for neovascular AMD.

语种英语
WOS记录号WOS:000303694800015
项目编号2006BAI02B05
资助机构Ministry of Science and Technology of the People&prime ; s Republic of China, Beijing, China
引用统计
被引频次:28[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51444
专题北京大学公共卫生学院
北京大学医学部管理机构_科学研究处
北京大学医学部管理机构_医学部
北京大学基础医学院
北京大学第一临床医学院_医院管理办公室
北京大学第二临床医学院_眼科
北京大学临床肿瘤学院_麻醉科
作者单位1.Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100871, Peoples R China
3.Third Mil Med Univ, Prevent Med Coll, Dept Hyg Toxicol, Changqing, Peoples R China
4.Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China
5.Beijing Ctr Dis Control & Prevent, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Tian, Jun,Qin, Xueying,Fang, Kai,et al. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population[J]. PHARMACOGENOMICS,2012,13(7):779-787.
APA Tian, Jun.,Qin, Xueying.,Fang, Kai.,Chen, Qing.,Hou, Jing.,...&Li, Xiaoxin.(2012).Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.PHARMACOGENOMICS,13(7),779-787.
MLA Tian, Jun,et al."Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population".PHARMACOGENOMICS 13.7(2012):779-787.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Association of genet(732KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Tian, Jun]的文章
[Qin, Xueying]的文章
[Fang, Kai]的文章
百度学术
百度学术中相似的文章
[Tian, Jun]的文章
[Qin, Xueying]的文章
[Fang, Kai]的文章
必应学术
必应学术中相似的文章
[Tian, Jun]的文章
[Qin, Xueying]的文章
[Fang, Kai]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。